EUVIMEDEUVIMED entdecken
Crossref

Ruthenium-106 (106Ru) plaque brachytherapy as salvage treatment for retinoblastoma following intravenous chemotherapy

Vijay Anand Reddy Palkonda, Aiswarya Ramachandran, Bolajoko Abidemi Adewara, Ritesh Verma, Vishal Raval, Swathi Kaliki

Brachytherapy · 2025

DOI: 10.1016/j.brachy.2024.06.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2025. Verfasst von Vijay Anand Reddy Palkonda und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Road no 2, Banjara Hills, Hyderabad, 500034 India; Department of…. Hauptthemen laut MEDLINE: Retinoblastoma, Brachytherapy, Salvage Therapy, Retinal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Hyderabad Eye Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To describe the clinical presentation and treatment outcomes of patients undergoing Ruthenium-106 (106Ru) plaque brachytherapy as salvage treatment for retinoblastoma (RB) following intravenous chemotherapy (IVC). METHODS: Retrospective chart review of 44 eyes of 42 patients. The indications for plaque brachytherapy included solid tumor recurrence (n=20; 45%), solid tumor residual (n=16; 36%), new subretinal seeds (n=5; 12%), and new solid tumor (n=3; 7%). RESULTS: The median age at the presentation was 12 months (range, 3-72 months). Based on ICRB classification, 8 (18%), 8 (18%), 16 (36%), and 5 (12%) tumors belonged to Groups B, C, D, and E, respectively. A median interval of 5 months (range 3-21 months) was noted between the last IVC cycle and plaque brachytherapy. The mean tumor height was four mm (range, 1.5-6 mm). All patients were treated with 106Ru plaque (round or notch) with a median total dose of 45 Gy (range, 40-55 Gy) delivered to the tumor apex. At a mean post plaque follow-up period of 28 months (median, 23 months; range, 3-132 months), tumor completely regressed in 25 eyes (56%). Tumor recurrence within the plaque site was noted in eight eyes (18%) associated with a type 2 regression pattern (75%). At the last follow-up, the globe salvage rate was 24 eyes (55%), while 2 patients (5%) died due to metastasis. CONCLUSION: 106RU plaque brachytherapy can be a useful salvage treatment for focal tumors (new or recurrent) following systemic IVC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinoblastomaBrachytherapySalvage TherapyRetinal NeoplasmsRuthenium RadioisotopesHumansMaleRetrospective StudiesFemaleInfantChild, PreschoolChildTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

EyePlaque brachytherapyRetinoblastomaRuthenium-106Salvage treatmentTumor

Substanzen

Ruthenium RadioisotopesRuthenium-106

Autor:innen und Institutionen

  • The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Road no 2, Banjara Hills, Hyderabad, 500034 India; Department of Radiation Oncology, Apollo Cancer Hospital, Hyderabad, India.
  • The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Road no 2, Banjara Hills, Hyderabad, 500034 India.
  • The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Road no 2, Banjara Hills, Hyderabad, 500034 India. Electronic address: drvishalraval@gmail.com.

Förderung

  • Hyderabad Eye Research Foundation

Zitieren

APA

Palkonda, V. A. R., Ramachandran, A., Adewara, B. A., Verma, R., Raval, V., & Kaliki, S. (2025). Ruthenium-106 (106Ru) plaque brachytherapy as salvage treatment for retinoblastoma following intravenous chemotherapy. Brachytherapy. https://doi.org/10.1016/j.brachy.2024.06.008

Vancouver

Palkonda VAR, Ramachandran A, Adewara BA, Verma R, Raval V, Kaliki S. Ruthenium-106 (106Ru) plaque brachytherapy as salvage treatment for retinoblastoma following intravenous chemotherapy. Brachytherapy. 2025. doi:10.1016/j.brachy.2024.06.008

BibTeX
@article{Palkonda2025,
  author = {Palkonda, Vijay Anand Reddy and Ramachandran, Aiswarya and Adewara, Bolajoko Abidemi and Verma, Ritesh and Raval, Vishal and Kaliki, Swathi},
  title = {Ruthenium-106 (106Ru) plaque brachytherapy as salvage treatment for retinoblastoma following intravenous chemotherapy},
  journal = {Brachytherapy},
  year = {2025},
  doi = {10.1016/j.brachy.2024.06.008}
}
Kostenlos starten →